Simone Meijs1, Tjibbe J Gardenbroek2, Mirjam A G Sprangers3, Willem A Bemelman2, Christianne J Buskens2, Geert R A M D'Haens1, Mark Löwenberg4. 1. Academic Medical Centre, Department of Gastroenterology & Hepatology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 2. Academic Medical Centre, Department of Surgery, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 3. Academic Medical Centre, Department of Medical Psychology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 4. Academic Medical Centre, Department of Gastroenterology & Hepatology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: m.lowenberg@amc.uva.nl.
Abstract
BACKGROUND AND AIMS: We compared health-related quality of life (HRQL) and disability in ulcerative colitis (UC) patients in remission with anti-tumor necrosis factor agents (TNF) or after restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA). METHODS: Two patient cohorts were studied. The first group consisted of patients in remission after RPC with IPAA (surgery group). The second group consisted of patients in remission with infliximab or adalimumab (medical group). For inclusion in the surgery group the pouch had to be functional for ≥1year and patients were excluded in case of postoperative complications. In the medical group, patients had to be on maintenance therapy with anti-TNF agents for ≥1year and in clinical remission. HRQL and disability outcomes were assessed using SF-36, COREFO, WPAI:UC and EORTC questionnaires. RESULTS: 60 patients were included, 30 patients in both groups. 58 out of 60 patients (97%) returned the completed questionnaires: 29 patients in the surgery group (median age 42 years [22-67]; 48% female) and 29 patients in the medical group (median age 45 years [19-68]; 65% female). Patient characteristics were comparable between the two groups. There were no significant differences in SF-36, WPAI:UC and EORTC questionnaires between both groups, except for the medication and stool frequency scale (COREFO questionnaire) that was significantly higher in the surgery vs. the medical group (p=0.004 and p<0.001, respectively). CONCLUSION: HRQL and disability were not different among the medical and surgical group, except for stool frequency and anti-diarrhea medication use that was significantly higher in surgically treated patients.
BACKGROUND AND AIMS: We compared health-related quality of life (HRQL) and disability in ulcerative colitis (UC) patients in remission with anti-tumornecrosis factor agents (TNF) or after restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA). METHODS: Two patient cohorts were studied. The first group consisted of patients in remission after RPC with IPAA (surgery group). The second group consisted of patients in remission with infliximab or adalimumab (medical group). For inclusion in the surgery group the pouch had to be functional for ≥1year and patients were excluded in case of postoperative complications. In the medical group, patients had to be on maintenance therapy with anti-TNF agents for ≥1year and in clinical remission. HRQL and disability outcomes were assessed using SF-36, COREFO, WPAI:UC and EORTC questionnaires. RESULTS: 60 patients were included, 30 patients in both groups. 58 out of 60 patients (97%) returned the completed questionnaires: 29 patients in the surgery group (median age 42 years [22-67]; 48% female) and 29 patients in the medical group (median age 45 years [19-68]; 65% female). Patient characteristics were comparable between the two groups. There were no significant differences in SF-36, WPAI:UC and EORTC questionnaires between both groups, except for the medication and stool frequency scale (COREFO questionnaire) that was significantly higher in the surgery vs. the medical group (p=0.004 and p<0.001, respectively). CONCLUSION: HRQL and disability were not different among the medical and surgical group, except for stool frequency and anti-diarrhea medication use that was significantly higher in surgically treated patients.
Authors: Lieke M Spekhorst; Bas Oldenburg; Ad A van Bodegraven; Dirk J de Jong; Floris Imhann; Andrea E van der Meulen-de Jong; Marieke J Pierik; Janneke C van der Woude; Gerard Dijkstra; Geert D'Haens; Mark Löwenberg; Rinse K Weersma; Eleonora A M Festen Journal: World J Gastroenterol Date: 2017-12-14 Impact factor: 5.742